

## 해외 바이오의약품 임상 현황 (2020.03.16~2020.03.22)

한국바이오의약품협회, 2020.3.24.  
출처: ClinicalTrials.gov

### ○ 미국 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	COVID-19	Drug: Sarilumab Drug: Placebo	Regeneron Pharmaceuticals Sanofi	Phase 2 Phase 3
NCT04206553	A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid	Bullous Pemphigoid	Drug: dupilumab Drug: Matching Placebo Drug: Oral corticosteroids (OCS)	Regeneron Pharmaceuticals Sanofi	Phase 2 Phase 3
NCT04231526	Pembrolizumab in Early Stage Colon Cancer	Colon Cancer	Drug: Pembrolizumab Procedure: Surgery	University of Chicago Merck Sharp & Dohme Corp.	Phase 2
NCT04171219	Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers	Advanced Malignant Solid Neoplasm Recurrent Malignant Solid Neoplasm	Biological: Pembrolizumab Drug: Talabostat Drug: Talabostat Mesylate	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04013672	Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence	Recurrent Glioblastoma	Drug: Pembrolizumab Drug: SurVaxM Drug: Sargramostim Drug: Montanide ISA 51	Manmeet Ahluwalia, MD Case Comprehensive Cancer Center	Phase 2
NCT03760575	Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)	Mesotheliomas Pleural	Drug: Pembrolizumab Procedure: Indocyanine Green (ICG) Image-Guided Surgery Drug: Cisplatin Drug: Pemetrexed	Abramson Cancer Center of the University of Pennsylvania	Phase 1
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3

### ○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3

### ○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3

### ○ 중국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04313647	A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers	Healthy	Biological: Low level of MSCs-Exo Biological: High level of MSCs-Exo	Ruijin Hospital Cellular Biomedicine Group Ltd.	Phase 1
NCT04099303	Phase I Clinical Trial in Healthy Children	Diphtheria Tetanus Pertussis	Biological: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed Biological: Diphtheria and Tetanus Combined Vaccine, Adsorbed Biological: Diphtheria-tetanus-acellular pertussis vaccine Biological: Diphtheria,tetanus,pertussis(acellul ar,component),poliomyelitis(inactiv ated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine	CanSino Biologics Inc. Henan Center for Disease Control and Prevention	Phase 1

### ○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3